Acute kidney disease following COVID-19 vaccination: a single-center retrospective study

Background Rare cases of de novo or relapsed kidney diseases associated with vaccination against coronavirus disease 2019 (COVID-19) have been increasingly reported. The aim of this study was to report the incidence, etiologies, and outcomes of acute kidney disease (AKD) following COVID-19 vaccination. Methods This retrospective study extracted cases from renal registry of a single medical center from 1 March 2021 to 30 April 2022, prior to the significant surge in cases of the Omicron variant of COVID-19 infection in Taiwan. Adult patients who developed AKD after COVID-19 vaccination were included. We utilized the Naranjo score as a causality assessment tool for adverse vaccination reactions and charts review by peer nephrologists to exclude other causes. The etiologies, characteristics, and outcomes of AKD were examined. Results Twenty-seven patients (aged 23 to 80 years) with AKD were identified from 1,897 vaccines (estimated rate of 13.6 per 1000 patient-years within the renal registry). A majority (77.8%) of vaccine received messenger RNA-based regimens. Their median (IQR) Naranjo score was 8 (6-9) points, while 14 of them (51.9%) had a definite probability (Naranjo score ≥ 9). The etiologies of AKD included glomerular disease (n = 16) consisting of seven IgA nephropathy, four anti-neutrophil cytoplasmic antibodies-associated glomerulonephritis (AAN), three membranous glomerulonephritis, two minimal change diseases, and chronic kidney disease (CKD) with acute deterioration (n = 11). Extra-renal manifestations were found in four patients. Over a median (IQR) follow-up period of 42 (36.5–49.5) weeks, six patients progressed to end-stage kidney disease (ESKD). Conclusion Besides glomerulonephritis (GN), the occurrence of AKD following COVID-19 vaccination may be more concerning in high-risk CKD patients receiving multiple doses. Patients with the development of de novo AAN, concurrent extra-renal manifestations, or pre-existing moderate to severe CKD may exhibit poorer kidney prognosis.

[1]  M. Vankalakunti,et al.  COVID-19 Vaccination and New Onset Glomerular Disease: Results from the IRocGN2 International Registry , 2022, Kidney360.

[2]  Yinshan Zhao,et al.  A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination , 2022, Journal of the American Society of Nephrology : JASN.

[3]  A. Kistler,et al.  Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased , 2022, Kidney International.

[4]  Y. Shoenfeld,et al.  Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune/inflammatory syndrome expand? , 2022, Clinical Rheumatology.

[5]  D. Ye,et al.  New‐onset autoimmune phenomena post‐COVID‐19 vaccination , 2021, Immunology.

[6]  R. Garg,et al.  Spectrum of neurological complications following COVID-19 vaccination , 2021, Neurological Sciences.

[7]  Shih-Hua Lin,et al.  Chronic Kidney Disease: Strategies to Retard Progression , 2021, International journal of molecular sciences.

[8]  J. Kellum,et al.  Acute kidney injury , 2021, Nature Reviews Disease Primers.

[9]  K. Jhaveri,et al.  Nephrotic syndrome and vasculitis following SARS-CoV-2 vaccine: true association or circumstantial? , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  R. Kim,et al.  Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. , 2021, JAMA cardiology.

[11]  V. D’Agati,et al.  De Novo and Relapsing Glomerular Diseases After COVID-19 Vaccination: What Do We Know So Far? , 2021, American Journal of Kidney Diseases.

[12]  C. King,et al.  Learning from the past: Taiwan’s responses to COVID-19 versus SARS , 2021, International Journal of Infectious Diseases.

[13]  T. Ortel,et al.  Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know , 2021, Blood.

[14]  S. Boyd,et al.  Antibody Response to COVID-19 vaccination in Patients Receiving Dialysis , 2021, medRxiv.

[15]  J. Teijaro,et al.  COVID-19 vaccines: modes of immune activation and future challenges , 2021, Nature Reviews Immunology.

[16]  V. Gushchin,et al.  Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia , 2021, The Lancet.

[17]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[18]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[19]  G. Koh Faculty Opinions recommendation of Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[20]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[21]  M. Gruber,et al.  Emergency Use Authorization of Covid Vaccines - Safety and Efficacy Follow-up Considerations. , 2020, The New England journal of medicine.

[22]  H. Schuitemaker,et al.  Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses , 2020, npj Vaccines.

[23]  D. Speiser,et al.  COVID-19: Mechanisms of Vaccination and Immunity , 2020, Vaccines.

[24]  Agati,et al.  Kidney Biopsy Findings in Patients with COVID-19. , 2020, Journal of the American Society of Nephrology : JASN.

[25]  Kenar D. Jhaveri,et al.  Acute kidney injury in patients hospitalized with COVID-19 , 2020, Kidney International.

[26]  R. Bellomo,et al.  Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference , 2020, Kidney international.

[27]  H. Shah,et al.  Vaccine-associated kidney diseases: A narrative review of the literature , 2019, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[28]  B. Hayman,et al.  A narrative review of the literature about people with intellectual disability who identify as lesbian, gay, bisexual, transgender, intersex or questioning , 2018, Journal of intellectual disabilities : JOID.

[29]  F. Cilurzo,et al.  Annual report on adverse events related with vaccines use in Calabria (Italy): 2012 , 2013, Journal of pharmacology & pharmacotherapeutics.

[30]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[31]  D. Greenblatt,et al.  A method for estimating the probability of adverse drug reactions , 1981, Clinical pharmacology and therapeutics.

[32]  OUP accepted manuscript , 2021, Clinical Kidney Journal.

[33]  M. Narayanan,et al.  Immune Dysfunction and Risk of Infection in Chronic Kidney Disease. , 2019, Advances in chronic kidney disease.